These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20209610)

  • 1. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Burris HA; Shipley D; Farley C; Macias-Perez IM; Barton J; Greco FA
    Cancer; 2010 May; 116(10):2448-54. PubMed ID: 20209610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
    Møller AK; Pedersen KD; Abildgaard J; Petersen BL; Daugaard G
    Acta Oncol; 2010 May; 49(4):431-5. PubMed ID: 20235750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
    Schuette K; Folprecht G; Kretzschmar A; Link H; Koehne CH; Gruenwald V; Stahl M; Huebner G
    Onkologie; 2009 Apr; 32(4):162-6. PubMed ID: 19372710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Shields AF; Zalupski MM; Marshall JL; Meropol NJ
    Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
    Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Comella P; Gambardella A; Farris A; Maiorino L; Natale D; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S;
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):133-9. PubMed ID: 15661564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.
    Polyzos A; Gogas H; Markopoulos C; Tsavaris N; Papadopoulos O; Polyzos K; Giannopoulos A
    Anticancer Res; 2009 Jul; 29(7):2851-6. PubMed ID: 19596973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Dupont J; Jensen HA; Jensen BV; Pfeiffer P
    Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.